The present study aimed to investigate the prescribing patterns of anticholinergics (anti-AChR) or β3-adrenergic agonists (β3A) in the pharmacotherapy of overactive bladder (OAB) and to evaluate the differences in the frequency of adverse events (AEs) between the two types of drugs using a large-scale medical claims database. This cohort study was conducted using the JMDC claims database between May 2015 and April 2023. Patient characteristics, prescription and treatment patterns of anti-AChR and β3A, and the incidence of AEs have been described. Overall, 70,936 patients were analyzed [mean age, 53.6 (standard deviation: 12.3) years]. Among women (48.5%; 34,439), 21.4% initially received anti-AChR and 27.2% received β3A; among men (51.5%; 36,497), 17.1% initially received anti-AChR and 34.3% received β3A. Most patients (79.6%; women, 83.5%; men, 75.8%) visited clinics. About 10% of patients had a treatment change: 5.6% switched the drug type (change from anti-AChR to β3A or vice versa), and 4.0% had an add-on of another drug type. The incidence rate of treatment change per 100 patient-years was higher with β3A in both women (12.39) and men (13.65). In the multivariable analysis, initial prescription with anti-AChR compared with β3A did not show any association with the risk of AEs. This large-scale database study revealed that treatment for OAB is often initiated with β3A and prescribed mainly at clinics. Changes or additions to initial prescriptions were as low as about 5%, indicating that raising awareness among physicians treating OAB is particularly important to improve the quality of life of patients with OAB. Our study also showed that the incidence of AEs was not associated with the initially prescribed drug type. Continued exploration is warranted to further clarify the risk of AEs with each prescription.

Kazuna Tsubouchi

Hisatomi Arima

Taiki Emoto

Hiroshi Nakazawa

Takahiro Kitano

Masashi Mikami

Chikao Aoyagi

Hiroshi Matsuzaki

Kosuke Tominaga

Naotaka Gunge

Takeshi Miyazaki

Yu Okabe

Nobuyuki Nakamura

Yuichiro Fukuhara

Masahiro Tachibana

Chizuru Nakagawa

Fumihiro Yamazaki

Nobuhiro Haga

Advances in Therapy

ADVANCES IN THERAPY 是一本国际、同行评审、快速出版（2 周内同行评审，接受后 3-4 周出版）期刊，致力于出版高质量的临床（所有阶段）、观察性、真实世界和围绕所有治疗领域的治疗和干预措施（包括设备）的发现、开发和使用进行健康结果研究。还鼓励与诊断和诊断、药物经济学、公共卫生、流行病学、生活质量以及患者护理、管理和教育相关的研究。该杂志吸引了广大医疗保健专业人士的兴趣，并发表原创研究、评论、通讯和信件。该杂志由全球读者阅读，并接收来自世界各地的投稿。 ADVANCES IN THERAPY 将考虑所有科学合理的研究，无论是正面的、证实性的还是负面的数据。无论提交的内容是否与国际和/或特定国家的受众有关，都欢迎提交，这在研究人员试图针对更具体的患者群体时至关重要。这种包容性的方法使期刊能够协助传播所有科学和道德上合理的研究。

Advances in Therapy is an international, peer-reviewed, rapid publication journal dedicated to publishing high-quality clinical research (at all stages), observational studies, real-world evidence, and health outcomes research related to interventions (including devices) across all therapeutic areas. The journal encourages research related to diagnostics, pharmacoeconomics, public health, epidemiology, quality of life, as well as patient care, management, and education. It attracts a wide audience of healthcare professionals and publishes original research, reviews, communications, and letters. The journal has a global readership and accepts submissions from around the world. Advances in Therapy considers all scientifically valid research, whether positive, confirmatory, or negative data. Submissions are welcome regardless of their relevance to international and/or specific national audiences, which is crucial when researchers aim to target more specific patient populations. This inclusive approach allows the journal to assist in disseminating all scientifically and ethically sound research.

《Advances in Therapy》是一本国际同行评审的快速出版期刊，致力于发表高质量的临床研究（涵盖所有阶段）、观察性研究、真实世界研究以及与所有治疗领域相关的干预措施（包括设备）的健康结果研究。期刊鼓励与诊断、药物经济学、公共卫生、流行病学、生活质量以及患者护理、管理和教育相关的研究。该杂志吸引了广泛的医疗保健专业人士的关注，发表原创研究、评论、通讯和信件。它的读者遍布全球，欢迎来自世界各地的投稿。《Advances in Therapy》将考虑所有科学合理的研究，无论是正面、证实性还是负面数据。无论提交的内容是否与国际或特定国家的受众相关，均欢迎投稿，这在研究者针对更具体的患者群体时尤为重要。这种包容性的方法使期刊能够协助传播所有科学和伦理上合理的研究。

Clinical Features and Current Pharmacotherapy of OAB in Practice: Ideal and Reality

临床实践中OAB的临床特征与当前药物治疗：理想与现实

Category	Quartile
医学	3
医学, 医学研究与实验	3
医学, 药学	3

Clinical Features and Current Pharmacotherapy of OAB in Practice: Ideal and Reality

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
PHARMACOLOGY & PHARMACY	2